Page 261 - 2021_04-Haematologica-web

Letters to the Editor
treatment of neoplastic bone metastases. Cancer Sci. 2009; 100(11):
1999-2005.
10. Woo JT, Kawatani M, Kato M, et al. Reveromycin A, an agent for
osteoporosis, inhibits bone resorption by inducing apoptosis specif- ically in osteoclasts. Proc Natl Acad Sci U S A. 2006;103(12):4729- 4734.
11. Muguruma H, Yano S, Kakiuchi S, et al. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. Clin Cancer Res. 2005;11(24 Pt 1):8822-8828.
12. Takeuchi K, Abe M, Hiasa M, et al. Tgf-Beta inhibition restores ter- minal osteoblast differentiation to suppress myeloma growth. PLoS
One. 2010;5(3):e9870.
13. Fulciniti M, Amin S, Nanjappa P, et al. Significant biological role of
sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011;
17(20):6500-6509.
14. Bat-Erdene A, Miki H, Oda A, et al. Synergistic targeting of Sp1, a
critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors. Oncotarget. 2016;7(48): 79064-79075.
15. Asano J, Nakano A, Oda A, et al. The serine/threonine kinase Pim- 2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia. 2011;25(7):1182-1188.
haematologica | 2021; 106(4)
1177